Clinical trials: Dengue
Dengue Fever
Evaluation Study of Dengue RDTs
RT-PCR and virus isolation are considered gold standard for diagnosis of Dengue from blood during first few days of infection. Serological methods such as enzyme-linked immunosorbent assays (ELISA), confirms the presence of a…
- Trial name
- NCT05580731
- Testing
- Diagnostic test: 5 different Rapid diagnostic test and Reference tests
- Where
- Pakistan
- Volunteers
- 430 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue Fever With Warning Signs
Factors Associated With Hospitalization for Dengue and Dengue Severity: Hospital-based Cohort Study on Reunion Island
In recent years, dengue has become endemic on La Réunion island, which has led to subsequent increase of secondary dengue infections, higher severity and higher mortality of the cases referred to the hospital.
- Trial name
- DENGUE-RUN (NCT05607472)
- Testing
- blood sampling, questionnary of health estate during 18 month
- Where
- France
- Volunteers
- 258 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Zika, Dengue
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Background: Mosquitoes and similar insects called sand flies carry parasites that can cause diseases. These viruses and parasites can spread quickly and be difficult to control.
- Conditions
- Zika, Dengue, Malaria, Chikungunya
- Trial name
- NCT03641339
- Testing
- One vector feeding, Four vector feeding
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
- Trial name
- NCT06006559
- Testing
- EYU688
- Where
- 27 sites in Brazil, Colombia and 5 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Dengue
Tetravalent Chimeric Dengue Vaccine Trial
The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus.
- Trial name
- NCT01110551
- Testing
- Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01072786
- Testing
- TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3
- Where
- 4 sites in United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and <18…
- Trial name
- NCT02302066
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- Where
- 3 sites in Dominican Republic, Panama and 1 more
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue.
- Trial name
- NCT06877039
- Testing
- Observational studies did not involve any interventions
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Dengue
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00375726
- Testing
- rDEN3/4delta30(ME)
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever With Warning Signs
Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs
Dengue Hemorrhagic Fever is a mosquito-borne viral disease endemic in the Philippines which caused multiple epidemics. Most points to the activation of the complement system secondary to humoral respond leading to cytokine…
- Trial name
- NCT05034809
- Testing
- Melatonin 20 MG
- Volunteers
- 140 people
- Sponsor
- Ilocos Training and Regional Medical Center
Dengue
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka…
- Trial name
- NCT02678455
- Testing
- TV005 vaccine
- Where
- Bangladesh
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
- Trial name
- NCT02193087
- Testing
- TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized
- Where
- 7 sites in United States
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
- Trial name
- NCT01254422
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- Where
- 4 sites in Malaysia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue, Severe Dengue
Dengue Serostatus Study in the Philippines
This is an observational study for 5 years, and aims to determine the risk of developing dengue among Philippine children who are eligible to receive the dengue vaccine during the DOH mass dengue vaccination, by dengue serostatus…
- Conditions
- Dengue, Severe Dengue, Dengue Fever, Virologically-confirmed Dengue
- Trial name
- NCT03465254
- Volunteers
- 2,996 people, healthy volunteers welcome
- Sponsor
- University of the Philippines
Microcephaly
Zika and Microcephaly: Case-control Study
It is suspected that zika virus infection during pregnancy is associated with microcephaly. The objective of this study is to investigate the occurrence of rash accompanied by three or more dengue-like signs and symptoms during…
- Trial name
- NCT02741882
- Testing
- Questionary
- Where
- Brazil
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Laboratório Sabin
Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue…
- Trial name
- DEN-04-IB (NCT06891950)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Healthy Volunteers, Dengue
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Background: Dengue is a viral disease spread by mosquitoes. Most people bitten by mosquitoes carrying dengue viruses do not get sick, but severe cases can cause shock, internal bleeding, and death.
- Conditions
- Healthy Volunteers, Dengue, Human Challenge Trial
- Trial name
- NCT07706686
- Testing
- rDEN2delta30-7169
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
This trial aims to test the safety of 2 doses of a T-cell priming specific cocktail of Dengue viruses peptides representing all 4 DENV serotypes and mounted on a gold nanoparticle.
- Trial name
- NCT04935801
- Testing
- LD vehicle-GNP, LD PepGNP-Dengue, HD vehicle-GNP
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd